Linked Data API

Filter

These are the filters currently being used to limit the search results. Click on the remove filter icon to remove the filter.

answer › answer text	%3Cp%3ENo Ministerial discussions have taken place. The National Institute for Health and Care Excellence %28NICE%29 is currently developing guidance on the use of Eylea for the treatment of myopic choroidal neovascularisation. NICE has published draft guidance that recommends use of the drug subject to a patient access scheme that makes the drug available to the National Health Service at a discounted price. NICE expects to publish final guidance this November. This is the first drug to be appraised through NICE%E2%80%99s new fast track appraisal process for treatments that can clearly demonstrate cost-effectiveness. Should the guidance remain unchanged%2C the NHS is committed to funding the treatment 30 days after NICE%E2%80%99s final guidance is published.%3C%2Fp%3E
min date	2017-09-05
answer › date of answer	2017-10-18
max date	2017-10-11

Sort by

This list shows the properties that you can sort by. Click on to sort in ascending order and to sort in descending order. The properties that you're currently sorting by are shown at the top of the list. Click on remove this sort to remove a sort and or to reverse the current sort order. Click on the remove all sorting icon to remove all the sorting. Note that sorting can significantly slow down the loading of the page.

View

Choose what information you want to view about each item. There are some pre-defined views, but starred properties are always present no matter what the view. You can star properties by clicking on the icon. The currently starred icons have a icon; clicking on it will unstar the property.

Items per page

Choose how many items to view on each page. The more items you view, the longer the page will take to load.

Show Search Form

Search Results

registered interest

date

exactly:

or between:
and

answering body

answering dept id

answering dept short name

answering dept sort name

hansard heading

house id

legislature


pref label

question text

tabling member constituency

tabling member printed

uin

answer

is ministerial correction

date of answer

exactly:

or between:
and

answer text

answering member constituency

answering member printed

question first answered

answering member


label

tabling member


label

768109

registered interest

date

10/10/2017

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Eylea: Macular Degeneration

house id

legislature

25259

pref label	House of Commons

question text

To ask the Secretary of State for Health, what discussions he has had with Lars Bruening, Bayer UK and Ireland CEO, as a result of the recognition by NICE of the merits of using Eylea to treat myopic choroidal neovascularisation.

tabling member constituency

Strangford

tabling member printed

Jim Shannon

uin

106900

answer

is ministerial correction

date of answer

18/10/2017

answer text

<p>No Ministerial discussions have taken place. The National Institute for Health and Care Excellence (NICE) is currently developing guidance on the use of Eylea for the treatment of myopic choroidal neovascularisation. NICE has published draft guidance that recommends use of the drug subject to a patient access scheme that makes the drug available to the National Health Service at a discounted price. NICE expects to publish final guidance this November. This is the first drug to be appraised through NICE’s new fast track appraisal process for treatments that can clearly demonstrate cost-effectiveness. Should the guidance remain unchanged, the NHS is committed to funding the treatment 30 days after NICE’s final guidance is published.</p>

answering member constituency

Winchester

answering member printed

Steve Brine

question first answered

18/10/2017 16:39:45

answering member

4067

label	Biography information for Steve Brine

tabling member

4131

label	Biography information for Jim Shannon